,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-04-17 23:49:00,"St. Jude Medical, Inc. ( STJ ), a large-cap medical devices and technology development company, reported first quarter fiscal 2012 adjusted earnings of 86 cents beating the Zacks Consensus Estimate of 83 cents per share and surpassing the year-ago earnings of 80 cents per share.",0.9206551313400269,0.0541597381234169,0.025185132399201393,positive,0.8664953708648682
1,2012-04-17 23:49:00,Adjusted earnings exclude extraordinary and one-time charges such as restructuring expenses to modernize manufacturing in the Cardiac Rhythm Management ( CRM ) segment.,0.016317594796419144,0.02603928931057453,0.9576430916786194,neutral,-0.009721694514155388
2,2012-04-17 23:49:00,"In the reported quarter, profit dropped 9% to $212 million (or 67 cents a share).",0.017771633341908455,0.9731414914131165,0.00908692181110382,negative,-0.9553698301315308
3,2012-04-17 23:49:00,"St. Jude reported net revenues of $1,395 million, up 1% year over year, beating the Zacks Consensus Estimate of $1,383 million.",0.9574832320213318,0.022686747834086418,0.01983008161187172,positive,0.9347965121269226
4,2012-04-17 23:49:00,Net sales rose 2% on constant currency basis.,0.9560084342956543,0.018884673714637756,0.025106826797127724,positive,0.9371237754821777
5,2012-04-17 23:49:00,Healthy growth across the company's smaller Atrial Fibrillation ( AF ) and Neuromodulation segments were largely offset by the decline in the core CRM division and the Cardiovascular segment.,0.05202868953347206,0.9070802330970764,0.040891118347644806,negative,-0.8550515174865723
6,2012-04-17 23:49:00,"On a geographic basis, revenues in the domestic and international markets were $665 million and $730 million, respectively.",0.02127978205680847,0.010285385884344578,0.9684348702430725,neutral,0.010994396172463894
7,2012-04-17 23:49:00,"Revenues from the sluggish CRM segment, St. Jude's mainstay, dropped 4% year over year (down 3% in terms of constant currency) to $735 million.",0.017272377386689186,0.9732498526573181,0.009477759711444378,negative,-0.9559774994850159
8,2012-04-17 23:49:00,"Within CRM, revenues from Implantable Cardioverter Defibrillator (ICD) declined 3% (down 2% in constant currency) to $450 million.",0.020453473553061485,0.9713487029075623,0.008197810500860214,negative,-0.9508952498435974
9,2012-04-17 23:49:00,"Sales from pacemaker division dipped 4%, both on reported and constant currency basis, to $285 million.",0.018854519352316856,0.9725797176361084,0.008565755560994148,negative,-0.9537252187728882
10,2012-04-17 23:49:00,"On a positive note, AF sales jumped 13% (up 14% in constant currency) to $221 million in the quarter.",0.9576826095581055,0.021604690700769424,0.020712779834866524,positive,0.936077892780304
11,2012-04-17 23:49:00,"Neuromodulation sales soared 12%, both on reported and constant currency basis, year over year to $103 million.",0.9529140591621399,0.018025897443294525,0.02906010113656521,positive,0.9348881840705872
12,2012-04-17 23:49:00,Revenues from St. Jude's Cardiovascular segment moved up 3% (up 3% in constant currency) to $336 million.,0.9557024836540222,0.020177599042654037,0.024119926616549492,positive,0.9355248808860779
13,2012-04-17 23:49:00,"Within Cardiovascular segment, structural heart devices sales increased 8% to $155 million offset by revenues from vascular offerings, which fell 2% year over year to $181 million.",0.12453106790781021,0.8585607409477234,0.0169081874191761,negative,-0.7340296506881714
14,2012-04-17 23:49:00,Gross margin declined to 72.7% from 73.5% a year ago.,0.01732986606657505,0.9744982719421387,0.008171790279448032,negative,-0.9571684002876282
15,2012-04-17 23:49:00,"Selling, general and administrative expenses, as a percentage of sales, declined to 35.1% from 37.3% a year ago.",0.018677787855267525,0.9734704494476318,0.007851710543036461,negative,-0.9547926783561707
16,2012-04-17 23:49:00,Research and development expenses (as a percentage of sales) edged down to 12.5% from 12.8%.,0.019781481474637985,0.9717469215393066,0.008471629582345486,negative,-0.9519654512405396
17,2012-04-17 23:49:00,Operating margins declined to 21.6% from 23.4% a year ago.,0.01779627613723278,0.9739820957183838,0.00822157971560955,negative,-0.9561858177185059
18,2012-04-17 23:49:00,"St. Jude exited fiscal 2011 with cash and cash equivalents of $1,053 million, 58.6% higher than the previous year.",0.9361880421638489,0.02780103124678135,0.036010921001434326,positive,0.9083870053291321
19,2012-04-17 23:49:00,"Long-term debt (including current obligations) decreased 7.3% year over year to $2,986 million.",0.01967630907893181,0.9726799726486206,0.007643718272447586,negative,-0.9530036449432373
20,2012-04-17 23:49:00,"For fiscal 2012, St. Jude revised its earnings forecast to the range of $3.44 - $3.49 per share from the earlier band of $3.43 - $3.48.",0.8016119003295898,0.06432022899389267,0.13406790792942047,positive,0.737291693687439
21,2012-04-17 23:49:00,"For the second quarter, the company expects adjusted earnings in the band of 86 cents - 88 cents a share.",0.39268723130226135,0.01655512861907482,0.5907576680183411,neutral,0.3761321008205414
22,2012-04-17 23:49:00,"St. Jude recently announced the CE Mark approval for its Ellipse ICD device, which is expected to help the company win ground in the highly competitive U.S. defibrillator space.",0.9434251189231873,0.017251912504434586,0.039322949945926666,positive,0.926173210144043
23,2012-04-17 23:49:00,St. Jude is consistently producing revenue growth and positive earnings surprises over the past several quarters.,0.951298713684082,0.01800405979156494,0.030697248876094818,positive,0.9332946538925171
24,2012-04-17 23:49:00,"We are impressed by its solid fundamentals, healthy growth trajectory, strong product mix, robust pipeline and cost management initiatives.",0.8861212134361267,0.011844178661704063,0.10203465074300766,positive,0.8742770552635193
25,2012-04-17 23:49:00,"While a host of new growth drivers (including new products and emerging markets) are expected to boost results in 2012 and beyond, we remain cautious about increased competition, a still soft CRM market and the dilutive impact of acquisitions.",0.7854141592979431,0.11844456940889359,0.09614133089780807,positive,0.6669695973396301
26,2012-04-17 23:49:00,A still choppy CRM space overhangs on St. Jude and its peers Medtronic ( MDT ) and Boston Scientific ( BSX ).,0.024500412866473198,0.8819677829742432,0.09353188425302505,negative,-0.8574673533439636
27,2012-04-17 23:49:00,Our long-term Neutral recommendation on St. Jude is in agreement with a short-term Zacks #3 Rank (Hold).,0.5755994915962219,0.016510769724845886,0.407889723777771,positive,0.5590887069702148
28,2012-04-17 23:49:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
29,2012-04-17 23:49:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
